Interactions nanoparticulaires et membranaires des protéines de l'oeil pour l'optimisation des thérapies en ophtalmologie

 

Elodie Boisselier

Centre de recherche du Centre hospitalier universitaire de Québec (CRCHUQ)

 

Domaine : neurosciences, santé mentale et toxicomanies

Programme chercheurs-boursiers - Junior 1

Concours 2016-2017

In Canada, more than 1.6 million people suffer from vision loss. Three diseases are involved in most cases of vision loss: age-related macular degeneration (AMD), glaucoma and cataracts. The causes of a large number of eye diseases are still unknown or unexplained. Basic research in the field of vision is therefore essential to better understand the etiology of these eye diseases in order to improve quality of life and care services to Canadians. Ophthalmic drugs are topically administrated as drops in 90% of cases.

However, only 10 to 20% of the active substance are absorbed under optimal conditions. The major limitation of most ophthalmic drugs is their limited penetrance in the eye. My research program thus aims to develop a new drug delivery system which will improve the efficiency of the medication used in ophthalmology. It is based on increasing the mucoadhesive properties of nanoparticles that are used as drug delivery systems. This new delivery system will thus improve the efficiency of these drugs and reduce their toxicity and cost.

My research program is also aimed at understanding the function of certain pigments and proteins of the eye and to identify new potential therapeutic targets. The phototoxicity of lipofuscin will be studied in order to better understand its role in the development of AMD. In addition, we will study the membrane behavior of proteins which belong to S100, annexins and neuronal calcium sensor families to decipher their role in physiological and pathological mechanisms of the eye.